High Hopes For Merck/AiCuris Late-Stage CMV Candidate Despite Chimerix Failure
This article was originally published in Scrip
Chimerix Inc.'s dramatic Phase III flop of its oral antiviral brincidofovir in human cytomegalovirus (HCMV) was not a disappointment to everyone. Merck & Co. Inc. and its little-known German partner AiCuris, which have Phase III data due later this year on their oral product letermovir (AIC246), suddenly found themselves in the lead with a very promising next-generation candidate for the treatment of HCMV.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.